Tenax to Present LEVEL Trial Results at ESC Congress 2026
Tenax confirmed it will present its Phase 3 LEVEL trial results at the ESC Congress 2026. This presentation reviews levosimendan's potential to treat PH-HFpEF.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day